genprowebdirectory
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Apellis
Artificial Intelligence
StockWatch: French Raid Shows Little Effect on Nvidia Price
Alex Philippidis
-
October 6, 2023
0
GEN Edge
StockWatch: Short Seller Briefly Dents Apellis Shares
Alex Philippidis
-
September 29, 2023
0
Drug Discovery
Apellis Axing 25% of Staff, Shifting Resources to GA Drug
Alex Philippidis
-
August 30, 2023
0
Drug Discovery
StockWatch: Apellis Shares Nosedive 73% on Safety Concerns
Alex Philippidis
-
August 3, 2023
0
Cancer
StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy
Alex Philippidis
-
February 24, 2023
0
Drug Discovery
Complementary Challenge: Apellis Throws Down the Gauntlet
Alex Philippidis
-
May 21, 2021
0
News
Apellis Pharmaceuticals – APL-9
Alex Philippidis
-
June 1, 2020
18
News
Apellis to Acquire Potentia, Four Years After Spinout
GEN Staff Writer
-
November 20, 2014
0
Scroll Up